Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum (preprint)

University of Oxford. Centre for Human Genetics. Nuffield Department of Medicine. Oxford, UK / University of Oxford. Oxford Institute (COI). Chinese Academy of Medical Science (CAMS). Oxford, UK.
Diamond Light Source Ltd, Harwell Science & Innovation Campus. Didcot, UK.
University of Oxford. Centre for Human Genetics. Nuffield Department of Medicine. Oxford, UK.
University of Oxford. Centre for Human Genetics. Nuffield Department of Medicine. Oxford, UK.
University of Oxford. Centre for Human Genetics. Nuffield Department of Medicine. Oxford, UK.
University of Oxford. Centre for Human Genetics. Nuffield Department of Medicine. Oxford, UK.
University of Oxford. Centre for Human Genetics. Nuffield Department of Medicine. Oxford, UK.
University of Oxford. Centre for Human Genetics. Division of Structural Biology, Nuffield Department of Medicine. Oxford, UK.
University of Oxford. Centre for Human Genetics. Nuffield Department of Medicine. Oxford, UK / Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
University of Oxford. Centre for Human Genetics. Division of Structural Biology, Nuffield Department of Medicine. Oxford, UK.
University of Oxford. Centre for Human Genetics. Division of Structural Biology, Nuffield Department of Medicine. Oxford, UK.
University of Oxford. Centre for Human Genetics. Nuffield Department of Medicine. Oxford, UK.
University of Oxford. Centre for Human Genetics. Nuffield Department of Medicine. Oxford, UK.
University of Oxford. Centre for Human Genetics. Division of Structural Biology, Nuffield Department of Medicine. Oxford, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK / Peter Medawar Building for Pathogen Research, Oxford, UK / University of Oxford. Nuffield Department of Clinical Neurosciences. Oxford, UK.
Peter Medawar Building for Pathogen Research, Oxford, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
University of Siena. Institute of Global Health. Siena, Brazil / University of Oxford. Department of Paediatrics. Oxford, UK.
Fundação Oswaldo Cruz. Fiocruz Amazônia. Instituto Leônidas e Maria Deane. Laboratório de Ecologia de Doenças Transmissíveis na Amazônia. Manaus, AM, Brasil.
Fundação Oswaldo Cruz. Fiocruz Amazônia. Instituto Leônidas e Maria Deane. Laboratório de Ecologia de Doenças Transmissíveis na Amazônia. Manaus, AM, Brasil.
Fundação Oswaldo Cruz. Fiocruz Amazônia. Instituto Leônidas e Maria Deane. Laboratório de Ecologia de Doenças Transmissíveis na Amazônia. Manaus, AM, Brasil.
Fundação de Vigilância em Saúde do Amazonas. Manaus, Amazonas, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de vírus respiratórios. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de vírus respiratórios. Rio de Janeiro, RJ, Brasil / Texas University. College Station. Department of Veterinary Integrative Biosciences. Texas, TX, United States.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de vírus respiratórios. Rio de Janeiro, RJ, Brasil.
NIHR Oxford Biomedical Research Centre. Oxford, UK / University of Oxford. Oxford Vaccine Group. Department of Paediatrics. Oxford, UK.
University of Kent and Greenwich. Medway School of Pharmacy. Viral Pseudotype Unit. Chatham Maritime, Kent ME4 4TB, UK.
University of Oxford. Oxford Institute (COI). Chinese Academy of Medical Science (CAMS). Oxford, UK / University of Oxford. Nuffield Department of Medicine. Oxford, UK / University of Oxford. MRC Weatherall Institute of Molecular Medicine. MRC Human Immunology Unit. Radcliffe Department of Medicine. Oxford, UK.
NIHR Oxford Biomedical Research Centre, Oxford, UK / Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
NIHR Oxford Biomedical Research Centre, Oxford, UK / Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
University of Oxford. Centre for Human Genetics. Nuffield Department of Medicine. Oxford, UK / National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK / Peter Medawar Building for Pathogen Research, Oxford, UK / NIHR Oxford Biomedical Research Centre, Oxford, UK / Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK / Peter Medawar Building for Pathogen Research, Oxford, UK / NIHR Oxford Biomedical Research Centre, Oxford, UK / Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
Oxford University Hospitals NHS Foundation Trust, Oxford, UK / Peter Medawar Building for Pathogen Research, Oxford, UK / Centre For Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK / Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand, Department of Medicine, University of Oxford, Oxford, UK.
South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa / Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Diamond Light Source Ltd, Harwell Science & Innovation Campus. Didcot, UK.
Diamond Light Source Ltd, Harwell Science & Innovation Campus. Didcot, UK.
South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa / Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa / Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Peter Medawar Building for Pathogen Research, Oxford, UK.
Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK / Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK / Siriraj Center of Research Excellence in Dengue & Emerging Pathogens, Dean Office for Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand.
Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK / Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK / Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK / Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK / Instruct-ERIC, Oxford House, Parkway Court, John Smith Drive, Oxford, UK.
Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK / Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.

Abstract in Portuguese

A pesquisa aponta que o soro de pessoas previamente infectadas por outras cepas é menos potente contra esta variante viral. O problema é observado de forma marcante entre os indivíduos anteriormente infectados pela variante Gama, identificada originalmente em Manaus e atualmente dominante no Brasil, assim como pela variante Beta, detectada pela primeira vez na África do Sul. Nestes casos, a capacidade de neutralizar a cepa Delta é onze vezes menor. O soro de pessoas vacinadas também tem potência reduzida contra a variante originária da Índia, mas os dados apontam que as vacinas continuam efetivas. A capacidade de neutralizar a cepa é 2,5 vezes menor para o imunizante da Pfizer e 4,3 vezes menor para o da Astrazeneca. Os autores do trabalho ressaltam que os índices são semelhantes aos verificados com as variantes Gama e Alfa – que emergiram no Brasil e no Reino Unido, respectivamente. Não há evidência de fuga generalizada da neutralização, diferentemente do registrado com a variante Beta – com origem na África do Sul.

Abstract

SARS-CoV-2 has undergone progressive change with variants conferring advantage rapidly becoming dominant lineages e.g. B.1.617. With apparent increased transmissibility variant B.1.617.2 has contributed to the current wave of infection ravaging the Indian subcontinent and has been designated a variant of concern in the UK. Here we study the ability of monoclonal antibodies, convalescent and vaccine sera to neutralize B.1.617.1 and B.1.617.2 and complement this with structural analyses of Fab/RBD complexes and map the antigenic space of current variants. Neutralization of both viruses is reduced when compared with ancestral Wuhan related strains but there is no evidence of widespread antibody escape as seen with B.1.351. However, B.1.351 and P.1 sera showed markedly more reduction in neutralization of B.1.617.2 suggesting that individuals previously infected by these variants may be more susceptible to reinfection by B.1.617.2. This observation provides important new insight for immunisation policy with future variant vaccines in non-immune populations.

Keywords in Portuguese

COVID-19
SARS-CoV-2
Reinfecção
Variante Delta

Keywords

COVID-19
SARS-CoV-2
Vaccine
Convalescent serum

Publisher

Elsevier

Later version

https://www.arca.fiocruz.br/handle/icict/51604

Citation

LIU, Chang et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell, p. 1-74, 25 Maio. 2021.

DOI

10.1016/j.cell.2021.06.020

Notes

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/47927

Type

Copyright

Open access

Sustainable Development Goals

Collections

Share

Statistics

Metadata

Author

Affilliation